Phenotypes Associated with This Genotype

Genotype
MGI:7578782

• Allelic Composition: Myl3^{tm1a(EUCOMM)Hmgu}/Myl3^{tm1a(EUCOMM)Hmgu}; Tg(Col2a1-cre/ERT)KA3Smac/0
• Genetic Background: involves: C57BL/6J * C57BL/6N * FVB/N
• Cell Lines: HEPD0622_5_G02

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

increased susceptibility to induced arthritis ( J:343166 )

♂ • tamoxifen-treated mice undergoing destabilization of the medial meniscus (DMM) surgery-induced osteoarthritis show more severe osteoarthritis progression at both 6- and 10-weeks post DMM surgery, showing reduced cartilage areas, aggravated synovial inflammation, partially increased osteophyte maturity, increased OARSI scores and enhanced cellular senescence of chondrocytes

♂ • the severity of DMM-induced osteoarthritis in tamoxifen-treated mice is comparable to that in controls after dynasore, a CME inhibitor, treatment or after RO4929097, a Notch pathway inhibitor, treatment, with reduced cartilage destruction and diminished numbers of senescent chondrocytes

skeleton

increased susceptibility to induced arthritis ( J:343166 )

♂ • tamoxifen-treated mice undergoing destabilization of the medial meniscus (DMM) surgery-induced osteoarthritis show more severe osteoarthritis progression at both 6- and 10-weeks post DMM surgery, showing reduced cartilage areas, aggravated synovial inflammation, partially increased osteophyte maturity, increased OARSI scores and enhanced cellular senescence of chondrocytes

♂ • the severity of DMM-induced osteoarthritis in tamoxifen-treated mice is comparable to that in controls after dynasore, a CME inhibitor, treatment or after RO4929097, a Notch pathway inhibitor, treatment, with reduced cartilage destruction and diminished numbers of senescent chondrocytes